VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer
Sara A. Hurvitz(University of Washington), Amanda Gillespie-Twardy(Düsseldorf University Hospital), Louisa L. Lo(Hollywood Private Hospital), Jennifer M. Suga(Kaiser Permanente Vallejo Medical Center), Andrea Silber, William Irvin, Jorge Nadal(Instituto Alexander Fleming), Hiba Jabbour, Ricardo Alvarez, Hyo S. Han(Moffitt Cancer Center), Rena D. Callahan, George Emile(Centre François Baclesse), Sarah C. Mutka(Twin Cities Spine Center), Hema Vankayala, Sibel Blau(University of Washington Tacoma), Igor Gorbatchevsky(Theravance Biopharma (United States)), Ernesto Korbenfeld(Harbin Medical University), Geronimo Rosselli, Sunil G. Babu, Ritesh Parajuli(University of California, Irvine), J. Martinez Rodriguez(Universidad Autónoma de Nuevo León), G. Kim(Yonsei University), Tayyaba Bashir, Sam Suzuki(Twin Cities Spine Center), Keren Moss(Twin Cities Spine Center), Miguel Martin(Hospital General Universitario Gregorio Marañón), for the VIKTORIA-1 Study Group, Delia Guaqueta, Fabrice André(Institut Gustave Roussy), Erica Stringer-Reasor, Juan Manuel Puig, Gerburg Wulf, Robert Wesolowski(The Ohio State University), Rachel M. Layman(The University of Texas MD Anderson Cancer Center), Yuly A. Remolina-Bonilla(Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán), Alistair Ring(Royal Marsden Hospital), David Chan, Antonio Giordano(Dana-Farber Cancer Institute), Giuseppe Curigliano(University of Milan), Massimo Cristofanilli(Cornell University), Jennifer Specht, Sung-Bae Kim(Ulsan College), Issam Makhoul(University of Arkansas for Medical Sciences), Brian Sullivan(Twin Cities Spine Center), Barbara Pistilli(Institut Gustave Roussy)
Cited by 4
Related Papers
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
|New England Journal of Medicine|2019|1k